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Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (CLL), and high microvascular density has
been found in CLL to be associated with a poor prognosis. In this study, we assessed serum levels of adiponectin in 69 patients
with Binet stage A B-CLL, and these values were retrospectively correlated with bone marrow (BM) microvessel area and serum
levels of vascular endothelial growth factor (VEGF), ﬁbroblast growth factor-2 (FGF-2), angiogenin, PECAM-1 (CD31), matrix
metalloproteinase-9 (MMP-9), interleukin-8 (IL-8), syndecan-1, and the percentage of CD38+ or ZAP-70+ CLL cells. The positive
correlation between serum levels of adiponectin and VEGF (P = .03) does not translate into an increase of the extent of BM
angiogenesis (P = .404), FGF-2 (P = .348), angiogenin (P = .402), and CD31 (P = .248) serum concentrations. Accordingly, IL-8
(P = .175), syndecan-1 (P = .06), and MMP-9 (P = .144) circulating levels were not likely to reﬂect adiponectin concentration.
Furthermore, patients with higher levels of adiponectin had a more favorable biological proﬁle as deﬁned by a lower number of
both CD38
− (r =− 0.294; P = .02) and ZAP-70+ (r =− 0.285; P = .04). Finally, we evaluated the presence of adiponectin in
B-CLL cells at gene expression level. RMA intensity values for adiponectin gene transcript denote a homogeneous low expression
in B-CLL cells, whereas VEGF transcript was highly expressed with a degree of interpatient variability. Overall, these data seem to
indicate that adiponectin could be involved as an antiangiogenic factor in B-CLL.
Copyright © 2009 Stefano Molica et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Angiogenesis is involved in the pathogenesis of B cell chronic
lymphocytic leukemia (CLL), and high microvascular den-
sity has been found in CLL to be associated with a poor
prognosis [1]. Several angiogenic growth factors are involved
in the pathogenesis of CLL. Serum vascular endothelial
growth factor (VEGF) and ﬁbroblast growth factor-2 (FGF-
2) were elevated in CLL patients, and high VEGF levels
also predicted disease progression in early stage CLL [2–
4]. A study including 216 CLL patients showed that those
withhigherconcentrationofVEGFreceptor-2(VEGFR-2)in
their peripheral blood lymphocytes had signiﬁcantly shorter
survival [5]. Angiogenin was expressed in CLL cells and in B
cells of normal donors, although its expression is higher in
B-cells CLL leukemic cells in comparison to normal B cells
[6].Frateretal.[7]demonstratedanupregulationofh ypo xia
inducible factor-1 alpha (HIF-1α) in CLL, suggesting that
localized tissue hypoxia is another important activator of
microvessel proliferation in CLL. Finally, matrix metallopro-
teinases (MMPs) have important roles in angiogenesis and
Bauvois et al. [8] found signiﬁcantly higher levels of MMP-9
in patients with CLL than in healthy controls.
Adiponectin, an adipose tissue-derived peptide, is
secreted by adipose cells and mimics many metabolic actions
of insulin [9]. Moreover, adiponectin is a regulator of energy2 Advances in Hematology
homeostasis and plays a role in the obesity-induced insulin
resistance and related complications [10].
More recently, it has been established a role for
adiponectin in the homeostasis of the cardiovascular system.
Adiponectin activated adenosine monophosphate kinase
(AMP-K) in endothelial cells, leading to enhanced in vivo
angiogenesis in murine Matrigel plug and rabbit cornea
assays, and inhibition of caspase 3-mediated apoptosis in
endothelial cells cultured in vitro [11, 12]. Otherwise,
Br˚ akenhielm et al. [13] showed that adiponectin inhibited
endothelial cell migration and proliferation in vitro and
neoangiogenesis in vivo in the chick embryo chorioallantoic
membrane (CAM) and cornea assays as well as decreased
angiogenesis and induced apoptosis in tumors.
With the aim to investigate the involvement of
adiponectin in angiogenesis in B-CLL, we have assessed
serum levels of adiponectin in 69 patients with Binet stage
A CLL, and these values were retrospectively correlated with
bone marrow microvessels area and serum levels of VEGF,
FGF-2,angiogenin,PECAM-1(CD31),MMP-9,interleukin-
8 (IL-8), syndecan-1, and the percentage of CD38+ or ZAP-
70+ CLL cells. Finally, we have evaluated the presence of
adiponectin and VEGF in B-CLL cells at gene expression
levels.
2.MaterialsandMethods
2.1. CLL Patients’ Cohorts. Two independent series of pre-
viously untreated Binet stage A CLL patients were investi-
gated. The ﬁrst series included 69 patients followed at the
Medical Oncology Department of Catanzaro; the second
cohort included 60 Binet stage A CLL patients from a
cooperative database speciﬁcally devised to investigate the
gene expression proﬁling of CLL cells.
2.2. Characteristics of Patients Evaluated for Serum
Adiponectin Level. Sixty-nine patients were selected based
on the availability of frozen serum samples. Their median
age was 64 years (range, 40–83), and the male to female ratio
was 41 to 28.
2.3.MeasurementofAdiponectinandOtherCytokines. Serum
adiponectin concentrations were measured in duplicate
with a quantitative sandwich enzyme immunoassay (ELISA)
technique (Human Adiponectin Quantikine Colorimetric
ELISA, R & D Systems, Minneapolis, Minn, USA). Calibra-
tions were carried out with human adiponectin standards.
Optical densities at 450nm were measured with a microtiter
plate reader. A standard curve was created by plotting the
logarithm of the mean absorbance of each standard versus
the logarithm of the cytokine concentration. Concentrations
were expressed in μg/mL, and the coeﬃcient of variation
(CV)reportedbythemanifacturerforinterassayandintraas-
saydeterminationsrangedfrom6.9%to8.8%andfrom2.5%
to 4.7%, respectively. Serum vascular endothelial growth fac-
tor (VEGF), FGF-2, angiogenin, PECAM-1 (CD31), MMP-
9, and IL-8 levels were measured with a quantitative ELISA
(Quantikine; R & D Systems, Minneapolis, Minn, USA).
Serumsyndecan-1 concentrationsweredetermined asserum
immune reactivity using a quantitative sandwich enzyme
immunoassay (ELISA) technique (syndecan-1 ELISA, Dia-
clone Research, Besancon, France).
2.4. Measurement of BM Angiogenesis. All blood vessels were
displayed in 6-μm sections of 4% paraformaldehyde-ﬁxed
paraﬃn embedded biopsies by staining endothelial cells
with the antifactor VIII-related antigen murine monoclonal
antibody M616 (IgG1; Dako, Glostrup, Denmark) and a
three-layer biotin-streptavidin peroxidase system described
previously [3]. The very few megakaryocytes also stained
with factor VIII-related antigen were easily distinguishable
by their morphology and size. Microvessel counts were
assessed in (4–6)×250 ﬁelds per section (covering almost
the whole section) and 2 sections for biopsy within a
superimposed 484-point square reticle of 12.5 × 10
−2
mm2/ﬁeld. Microvessels (i.e., capillaries and small venules)
were identiﬁed as tubes with a single layer of endothelial
cells, either without or with a lumen not exceeding 10μm.
Aplanimetricpoint-countmethodwasappliedtocountonly
thosemicrovesselstransverselysectionedwhichoccupiedthe
reticle intersection points.
2.5. Detection of ZAP-70. Mononuclear cells (MNCs) from
CLL cases were isolated by Ficoll-Hypaque (Seromed,
BiochromKG,Berlin,Germany)densitygradientcentrifuga-
tion, stained with CD19-PE and CD3 PE-CY7 (Becton Dick-
inson, San Diego, Calif, USA), and ﬁxed and permeabilized
with ﬁx & perm reagents (Caltag Laboratories, Burlingame,
Calif, USA) at the concentration of 5 × 105 cells/50μL. The
cells were subsequently exposed to ZAP-70 mAb conjugated
with FITC (clone 2F3.2, Upstate, lake Placid, NY, USA) and
analyzed by ﬂow cytometry (FacsCalibur Becton Dickinson).
A CD33 FITC (Becton Dikinson) mAb of the same IgG1
subclass was used as negative control of ZAP-70 [14].
2.6. CD-38 Evaluation. Direct immunoﬂuorescent staining
was performed with CD19 FITC/PE, CD23 PE, CD38
PE, and Cy-Chrome (Becton Dickinson & Co., Sunnyvale,
Calif, USA). CD19 FITC, CD23 PE, and CD5 Cy-Chrome
were used to assess the proportion of CLL cells in the
suspensions; the proportion of CD38-positive leukemic cells
was determined by triple staining for CD19 FITC, CD38 PE,
and CD5 Cy-Chrome. The cells were analyzed using a FACS-
sort ﬂow cytometer (Becton Dickinson & Co).
2.7. Gene Expression. T cells, NK cells, and monocytes were
removed from PBMNC of CLL patients by CD3, CD56,
CD16, and CD14 monoclonal antibody (mAb) treatment
(Becton Dickinson, San Diego, Calif, USA) followed by
magnetic beads (Goat Anti-Mouse IgG D ynabeads, Dynal
Biotech ASA, Oslo, Norway). The purity of the B cells
was assessed by ﬂow cytometry by the determination of
the proportions of CD5/CD19/CD23 triple positive B cells
in the suspension. Puriﬁed normal peripheral blood B
cells were obtained from six normal donors. Total RNA
was isolated using the TRIzol Reagent (Life Technologies,Advances in Hematology 3
Inc., Rockville, Md, USA) and then puriﬁed using the
RNeasy total RNA Isolation Kit (Qiagen, Valencia, Calif,
USA). Preparation of biotin-labeled cRNA, hybridization
to GeneChip Human Genome U133A Arrays (Aﬀymetrix
Inc., Santa Clara, Calif, USA) and scanning of the chips
(7G Scanner, Aﬀymetrix Inc., Santa Clara, Calif, USA)
were carried out according to manufacturer’s protocols.
T h ei m a g e sw e r ea n a l y s e du s i n gA ﬀymetrix GeneChip
Operating Software (GCOS) 1.4, and the probe level data
were converted to expression values using the Bioconductor
function for Robust Multiarray average (RMA) procedure,
in which perfect match values are background adjusted
and normalized using quantile-quantile normalization, as
previously described [14]. Expression data of the 60 B-CLLs
proprietary database were deposited in the National Centre
for Biotechnology Information’s Gene Expression Omnibus
(GEO; http://www.ncbi.nlm.nih.gov/geo/) and are available
through GEO Series accession number GSE11038
2.8. Statistics. Spearman correlations, Mann-Whitney test,
and the corrected 2c test were applied to compare groups.
3. Results
3.1. Adiponectin Concentration in CLL Patients. Adiponectin
serum levels in Binet stage A patients ranged between 1.1
and 22.0μg/mL (median, 5.88μg/mL). In healthy age- and
sex-matched controls the median was 5.4μg/mL (range, 1.2–
11.8μg/mL). Overall, no diﬀerence could be found between
patients with CLL and healthy controls (Mann-Whitney test,
P = .658). Interestingly either normal controls or CLL
patients had a body mass index (BMI) <30Kg/m2.
3.2. Correlation between Adiponectin and Other Angiogenic
Factors. In order to assess the potential angiogenic of
adiponectin in CLL we analyzed its correlation with other
angiogenic factors. Serum levels of adiponectin reﬂected
VEGF concentration (r = 0.337; P = .03; see Figure 1);
however, such an association did not translate into an
increase of the extent of bone marrow angiogenesis in
patients with higher adiponectin levels. In 27 patients with
available data we failed to demonstrate any association
between microvessel area and adiponectin (P = .404).
A similar behavior was observed for FGF-2 (P = .348),
angiogenin (P = .402), and CD31 (P = .248) whose serum
concentrations did not change as a function of adiponectin
levels. Accordingly, IL-8 (P = .175), syndecan-1 (P = .06),
and MMP-9 (P = .144) circulating levels were not likely to
reﬂect adiponectin concentrations.
3.3. Adiponectin and Biologic Proﬁle in CLL. Given the
transcriptional characteristics of CD38+ cells in CLL whose
VEGF level is 2-3 fold higher in comparison to CD38
− cells
[15], we sought for correlation between CD38-expression
and adiponectin concentration. The low angiogenic activity
of adiponectin was also reﬂected in the inverse correlation
between CD38 and adiponectin (r =− 0.294; P = .02;
see Figure 2). Furthermore, patients with higher levels of
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Figure 1: Correlation between serum levels of adiponectin and
VEGF. The analysis denotes a signiﬁcant direct correlation (r =
0.337; P = .003).
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Figure 2: Correlation between serum levels of adiponectin and
percentage of CD38-positive B-CLL cells. The analysis denotes a
signiﬁcant inverse correlation (r =− 0.294; P = .02).
adiponectin had a more favorable biological proﬁle as
deﬁned by a lower number of ZAP-70+ cells (r =− 0.285;
P = .04).
3.4. Evaluation of Adiponectin and VEGF Gene Transcript
in CLL. We examinated the presence of adiponectin in B-
CLL cells at gene expression levels. RMA intensity values
for adiponectin gene transcript denote a homogeneous low
expression in B-CLL cells (Figure 3(a)). The same does not
apply for VEGF transcript which was highly expressed with a
degree of interpatients variability (Figure 3(b)).
4. Discussion
In this study we failed to demonstrate a proangiogenic
role for adiponectin in B-CLL. As a matter of fact, the
positive correlation between adiponectin and VEGF serum
levels observed in such patients does not translate into4 Advances in Hematology
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Figure 3:AbsoluteRMAintensityvaluesforadiponectin(ADIOQ)(a)andVEGF(b)transcriptin60B-CLLpatientsassessedbymicroarray
analysis.
an increase of other parameters involved in angiogenesis,
such as BM microvessel area, serum concentrations of FGF-
2, angiogenin, IL-8, syndecan-1, CD31, and MMP-9.
We previously demonstrated an association between
increased serum VEGF concentration and modern prog-
nostic factors in B-cell CLL [16]. Using high-speed cell
sorting and subsequent gene expression proﬁling, Pepper
et al. [15] investigated the transcriptional characteristics of
puriﬁed CD38+ and CD38
− subsets from a CLL patient
and demonstrated 2-3 fold increased levels of VEGF in
CD38+ cells. The inverse correlation between circulating
levels of adiponectin and either CD38 or ZAP-70 expression,
observed in this study, suggests that B-CLL patients with
high-serum adiponectin levels may have a less aggressive
phenotype.
Finally, evaluating adiponectin and VEGF gene tran-
scripts, we have demonstrated a homogeneous low expres-
sion of adiponectin gene transcripts in B-CLL cells, whereas
VEGF transcripts were highly expressed with a degree of
interpatient variability. These results suggest that leukemic
cells have a limited role in the production of circulating
adiponectin levels. On the contrary both adiponectin recep-
tor 1 (AdipoR1) and AdipoR2 mRNA were highly expressed
by CLL cells [14]. Whether the eﬀect of adiponectin on
cell proliferation might be most likely adiponectin receptor-
mediated also in CLL as in other models is not clear so far
[17].
Angiogenesis is controlled by the balance between
molecules that have positive and negative regulatory activity
and this concept led to the notion of angiogenic switch,
which depends on an increased production of one or more
positive regulators of angiogenesis [18]. Endothelial cell
turnover in the healthy adult organism is low, the quiescence
being maintained by the dominant inﬂuence of endogenous
angiogenesis inhibitors over angiogenic stimuli. In patho-
logical situations angiogenesis may be triggered not only
by the overproduction of proangiogenic factors, but also by
the downregulation of inhibitory factors. Also in B-CLL, the
balance of pro- and antiangiogenic factors appears to have a
critical role in its pathogenesis. Kay et al. [19] indicated that
B-CLL cells expresssed pro- and antiangiogenic molecules,
and Shanafelt and Kay [20] observed, that the ratio of
proangiogenic FGF-2 and antiangiogenic thrombospondin-
1 (TSP-1) correlated with the time to treatment. Ligation
of TSP-1 receptor appears to induce a caspase-independen
apoptotic death in CLL B-cells, which occurs even if theseAdvances in Hematology 5
cells are cocultured with autologous marrow stromal cells or
ﬁbroblasts, therefore suggesting that the angiogenic switch is
related to clinical progression in B-cell CLL.
The data presented in this study seem to indicate
that adiponectin could be involved as an antiangiogenic
factor in B-cell CLL. Our data are in keeping with those
published by Bora et al. [21], who have demonstrated that
adiponectin acts as an antiangiogenic protein in the mouse
model of laser-induced choroidal neovascularization and
inhibits the expression of VEGF mRNA and protein in the
choroidal tissue. Finally, Mahadev et al. [22] demonstrated
that adiponectin suppressed VEGF-stimulated human coro-
nary endothelial cells migration via cAMP/PKA-dependent
signalling, with important implications for a regulatory role
of adiponectin in vascular processes associated with diabetes
and atherosclerosis.
It is well established that the angiogenic phenotype
results from the imbalance between positive and negative
regulator factors, so that the contribution of each “classical”
and/or “nonclassical” angiogenic factor may play a diﬀerent
role in the deﬁnition of the angiogenic phenotype [23].
In this context, adiponectin can be considered as one of
the “nonclassical” angiogenic factors. A detailed knowledge
of the mechanism of action and expression as well as
the interactions of the new “non-classical” endogenous
regulators of angiogenesis with their receptors will provide
new insights that are essential for the future development
of chemical compounds that can modulate the activity of
these new “non-classical” endogenous regulators and may
have potential for antitumor activity. In fact, tumors and
other angiogenic pathologies exploit redundant mechanisms
toinduceangiogenesis,andneutralizationofmutiplefactors,
including both “classical” and “nonclassical” regulators may
be required to suppress tumor growth. The recognition
by clinicians of the angiogenesis-modulatory properties of
common drugs is important in the development and future
application of angiogenesis inhibitory therapies.
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